Luminal delivery of phosphatidyl rich phospholipids appears to reduce mucosal inflammatory activity in a high proportion of patients with chronically active ulcerative colitis. The simplicity and apparent safety of this therapeutic approach offers new insights into the importance of the mucus barrier in the pathogenesis and treatment of ulcerative colitis.
No takes yet. Share an insight, caveat, or question.
Peter G. Gibson (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: